Hepatitis B (HBV) Partner‐ready status, page-7

Well I have the money and I have chosen to invest it in what I think are much better opportunities.

There is a lack here of any serious model for such an MC. Where is the analysis that would support a NPV of greater than $200 million? Posting a random large numbers and "biggreenbeast" is not analysis.

It is a shame that something like a PFS or DFS is not required for biotechs. It would be great if we had from BIT a PFS compiled by an independent consultant and signed off by a competent person laying out the business model and company valuation. I understand why there isn't, but it still makes if very hard for the average investor to value a company like BIT.